Kidswell Bio Corporation
TSE:4584
Intrinsic Value
Kidswell Bio Corp. engages in the research and development of biopharmaceutical products. [ Read More ]
The intrinsic value of one Kidswell Bio Corporation stock under the Base Case scenario is 419.42 JPY. Compared to the current market price of 147 JPY, Kidswell Bio Corporation is Undervalued by 65%.
Valuation Backtest
Kidswell Bio Corporation
Run backtest to discover the historical profit from buying and selling Kidswell Bio Corporation stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Kidswell Bio Corporation
Current Assets | 5B |
Cash & Short-Term Investments | 2.2B |
Receivables | 481.9m |
Other Current Assets | 2.4B |
Non-Current Assets | 161.7m |
PP&E | 1.4m |
Intangibles | 1.7m |
Other Non-Current Assets | 158.6m |
Current Liabilities | 2B |
Accounts Payable | 72.3m |
Other Current Liabilities | 1.9B |
Non-Current Liabilities | 1.8B |
Long-Term Debt | 1.7B |
Other Non-Current Liabilities | 41.6m |
Earnings Waterfall
Kidswell Bio Corporation
Revenue
|
2.6B
JPY
|
Cost of Revenue
|
-1.3B
JPY
|
Gross Profit
|
1.3B
JPY
|
Operating Expenses
|
-2.4B
JPY
|
Operating Income
|
-1.1B
JPY
|
Other Expenses
|
-127.5m
JPY
|
Net Income
|
-1.2B
JPY
|
Free Cash Flow Analysis
Kidswell Bio Corporation
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
Kidswell Bio Corporation's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Score
Kidswell Bio Corporation's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Kidswell Bio Corporation's solvency score is 34/100. The higher the solvency score, the more solvent the company is.
Score
Kidswell Bio Corporation's solvency score is 34/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Kidswell Bio Corporation
According to Wall Street analysts, the average 1-year price target for Kidswell Bio Corporation is 816 JPY with a low forecast of 808 JPY and a high forecast of 840 JPY.
Shareholder Return
Price
Kidswell Bio Corporation
Average Annual Return | -20.09% |
Standard Deviation of Annual Returns | 34.25% |
Max Drawdown | -88% |
Market Capitalization | 5.6B JPY |
Shares Outstanding | 37 817 307 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Kidswell Bio Corp. engages in the research and development of biopharmaceutical products. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 39 full-time employees. The company went IPO on 2012-11-30. The biosimilar business is engaged in the research, development and provision of filgrastim biosimilar products and pegfilgrastim biosimilar products for cancer, darbepoetin alfa biosimilar products for renal diseases, and ranibizumab biosimilar products for eye diseases. The new biopharmaceutical business is engaged in the research and development of anti-RAMP2 antibodies for cancer and eye diseases, as well as new antibodies. The new biotechnology business is engaged in the development of regenerative medicine products that utilize intracardiac stem cells for pediatric congenital heart diseases, and regenerative medicine products that utilize dental pulp stem cells for cleft lip and palate and intestinal ganglion cell deficiency diseases, as well as the joint research business with universities.
Contact
IPO
Employees
Officers
The intrinsic value of one Kidswell Bio Corporation stock under the Base Case scenario is 419.42 JPY.
Compared to the current market price of 147 JPY, Kidswell Bio Corporation is Undervalued by 65%.